Nurexone Biologic Stock Cash Flow From Operations
| NRX Stock | 0.70 0.04 5.41% |
NurExone Biologic fundamentals help investors to digest information that contributes to NurExone Biologic's financial success or failures. It also enables traders to predict the movement of NurExone Stock. The fundamental analysis module provides a way to measure NurExone Biologic's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to NurExone Biologic stock.
NurExone |
NurExone Biologic Company Cash Flow From Operations Analysis
NurExone Biologic's Operating Cash Flow reveals the quality of a company's reported earnings and is calculated by deducting company's income taxes from earnings before interest, taxes, and depreciation (EBITDA). In other words, Operating Cash Flow refers to the amount of cash a firm generates from the sales or products or from rendering services. Operating Cash Flow typically excludes costs associated with long-term investments or investment in marketable securities and is usually used by investors or analysts to check on the quality of a company's earnings.
Current NurExone Biologic Cash Flow From Operations | (2.94 M) |
Most of NurExone Biologic's fundamental indicators, such as Cash Flow From Operations, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, NurExone Biologic is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Operating Cash Flow shows the difference between reported income and actual cash flows of the company. If a firm does not have enough cash or cash equivalents to cover its current liabilities, then both investors and management should be concerned about the company having enough liquid resources to meet current and long term debt obligations.
| Competition |
In accordance with the recently published financial statements, NurExone Biologic has (2.94 Million) in Cash Flow From Operations. This is 100.56% lower than that of the Biotechnology sector and 104.7% lower than that of the Health Care industry. The cash flow from operations for all Canada stocks is 100.3% higher than that of the company.
NurExone Cash Flow From Operations Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses NurExone Biologic's direct or indirect competition against its Cash Flow From Operations to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of NurExone Biologic could also be used in its relative valuation, which is a method of valuing NurExone Biologic by comparing valuation metrics of similar companies.NurExone Biologic is currently under evaluation in cash flow from operations category among its peers.
NurExone Fundamentals
| Return On Equity | -2.54 | ||||
| Return On Asset | -1.14 | ||||
| Current Valuation | 46.26 M | ||||
| Shares Outstanding | 70.84 M | ||||
| Shares Owned By Insiders | 4.75 % | ||||
| Number Of Shares Shorted | 32.31 K | ||||
| Price To Book | 13.66 X | ||||
| EBITDA | (4.09 M) | ||||
| Net Income | (3.64 M) | ||||
| Total Debt | 1.98 M | ||||
| Book Value Per Share | 0.04 X | ||||
| Cash Flow From Operations | (2.94 M) | ||||
| Short Ratio | 0.58 X | ||||
| Earnings Per Share | (0.11) X | ||||
| Target Price | 4.03 | ||||
| Beta | -0.091 | ||||
| Market Capitalization | 49.59 M | ||||
| Total Asset | 2.17 M | ||||
| Retained Earnings | (14.06 M) | ||||
| Working Capital | 74 K | ||||
| Net Asset | 2.17 M |
About NurExone Biologic Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze NurExone Biologic's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NurExone Biologic using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NurExone Biologic based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for NurExone Stock Analysis
When running NurExone Biologic's price analysis, check to measure NurExone Biologic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NurExone Biologic is operating at the current time. Most of NurExone Biologic's value examination focuses on studying past and present price action to predict the probability of NurExone Biologic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NurExone Biologic's price. Additionally, you may evaluate how the addition of NurExone Biologic to your portfolios can decrease your overall portfolio volatility.